Skip to main content

Advertisement

SpringerLink
Log in

Cardiac manifestation of the hypereosinophilic syndrome: new insights

  • Review
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Cardiac manifestation is the major cause of morbidity in patients with hypereosinophilic syndrome (HES). Clinical features range from heart failure to arterial embolism, which are caused by thickening of the endocardium and mural left ventricular thrombosis. Modern magnetic resonance imaging and echocardiography are able to detect fibrosis, eosinophilic infiltrate and thrombi to stage the fibrotic evolution of the disease. Treatment of HES involves standard medication for heart failure, anticoagulant therapy, immunosuppressive therapy and potentially surgical resection. The outcome of HES depends on both the progression of endocardial fibrosis and associated complications and the 5-year mortality is estimated at 30%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Klion AD, Bochner BS, Gleich GJ et al (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117:1292–1302

    Article  PubMed  Google Scholar 

  2. Corssmit EP, Trip MD, Durrer JD (1999) Loffler’s endomyocarditis in the idiopathic hypereosinophilic syndrome. Cardiology 91:272–276

    Article  CAS  PubMed  Google Scholar 

  3. Parrillo JE (1990) Heart disease and the eosinophil. N Engl J Med 323:1560–1561

    CAS  PubMed  Google Scholar 

  4. Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54:1–27

    Article  CAS  Google Scholar 

  5. Weller PF, Bubley GJ (1994) The idiopathic hypereosinophilic syndrome. Blood 83:2759–2779

    CAS  PubMed  Google Scholar 

  6. Chang HW, Leong KH, Koh DR, Lee SH (1999) Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 93:1651–1657

    CAS  PubMed  Google Scholar 

  7. Löffler W. Endocarditis parietalis fibroplastica mit Bluteosinophilie. Schweiz Med Wochenschr 1936, 65:817–820 and Klinische Wochenschrift, Berlin, 1935, 14:297–299

    Google Scholar 

  8. Fletcher S, Bain B (2007) Diagnosis and treatment of hypereosinophilic syndromes, current opinion in hematology. Curr Opin Hematol 14(1):37–42

    Article  CAS  PubMed  Google Scholar 

  9. Baxter EJ, Hochhaus A, Bolufer P et al (2002) The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 11:1391–1397

    Article  CAS  PubMed  Google Scholar 

  10. Score J, Curtis C, Waghorn K et al (2006) Identification of a novel imatinib responsive KIF5B–PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 20:827–832

    Article  CAS  PubMed  Google Scholar 

  11. Walz C, Curtis C, Schnittger S et al (2006) Transient response to imatinib in a chronic eosinophilic leukaemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2–PDGFRA fusion gene. Genes Chromosomes Cancer 45(10):950–956

    Article  CAS  PubMed  Google Scholar 

  12. Young JD, Peterson CG, Venge P, Cohn ZA (1986) Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 321(6070):613–616

    Article  CAS  PubMed  Google Scholar 

  13. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ (1987) Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet 1(8534):643–647

    Article  CAS  PubMed  Google Scholar 

  14. Ruggeri ZM (2006) Platelet interactions with vessel wall components during thrombogenesis. Blood Cells Mol Dis 36(2):145–147

    Article  CAS  PubMed  Google Scholar 

  15. Rohrbach MS, Wheatley CL, Slifman NR, Gleich GJ (1990) Activation of platelets by eosinophil granule proteins. J Exp Med 172(4):1271–1274

    Article  CAS  PubMed  Google Scholar 

  16. Ogbogu P, Rosing DR, Horne MD (2007) Cardiovascular manifestation of hypereosinophilic syndromes. Immunol Allergy Clin North Am 27(3):457–475

    Article  PubMed  Google Scholar 

  17. Roufosse F, Cogan E, Goldman M (2004) Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 59:673–689

    Article  CAS  PubMed  Google Scholar 

  18. Parrillo JE, Borer JS, Henry WL, Wolff SM, Fauci AS (1979) The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med 67(4):572–582

    Article  CAS  PubMed  Google Scholar 

  19. Roufosse F, Goldman M, Cogan E (2006) Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med 27:158–170

    Article  PubMed  Google Scholar 

  20. Jaffe ES, Harris NL, Stein H et al (2001) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARSPress, Lyon

    Google Scholar 

  21. Cohen J, Goodwin J, Spry JF et al (1980) Arrhythmias in patients with hypereosinophilia: a comparison of patients with and without Loffler’s endomyocardial disease. Postgrad Med J 56:828–832

    Article  CAS  PubMed  Google Scholar 

  22. Oh JK, Seward JB, Tajik AJ (1999) The echo manual, 2nd edn edn. Lippincott-Raven, Philadelphia

    Google Scholar 

  23. Braunwald E (2005) The cardiomyopathies. In: Zipes D et al (eds) Braunwald’s heart disease, 7th edn. Saunders, Philadelphia

    Google Scholar 

  24. Shah R, Ananthasubramaniam K (2006) Evaluation of cardiac involvement in hypereosinophilic syndrome: complementary roles of transthoracic, transesophageal, and contrast echocardiography. Echocardiography 23(8):689–691

    Article  PubMed  Google Scholar 

  25. Jeserich M, Konsantinides S, Pavlik G, Bode C, Geibel A (2009) Non-invasive imaging in the diagnosis of acute viral myocarditis. Clin Res Cardiol 98(12):753–763

    Article  PubMed  Google Scholar 

  26. Eitel I, Fuernau G, Walther C, Razek V, Kivelitz D, Schuler G, Thiele H (2008) Delayed enhancement magnetic resonance imaging in isolated noncompaction of ventricular myocardium. Clin Res Cardiol 97(4):280–283

    Article  Google Scholar 

  27. Hombach V, Merkle N, Kestler HA, Torzewski J, Kochs M, Marx N, Nusser T, Burgstrahler C, Rasche V, Wöhrle J (2008) Characterization of patients with acute chest pain using cardiac magnetic resonance imaging. Clin Res Cardiol 97(10):760–767

    Article  PubMed  Google Scholar 

  28. Debl K, Djavidani B, Luchner A et al (2008) Time course of eosinophilic myocarditis visualized by CMR. J Cardiovasc Magn Reson 10:21

    Article  PubMed  Google Scholar 

  29. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH (1982) NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 97(1):78–92

    CAS  PubMed  Google Scholar 

  30. Weller PF (1991) The immunobiology of eosinophils. N Engl J Med 324:1110–1118

    Article  CAS  PubMed  Google Scholar 

  31. Jourdain P, Joneau G, Juilliere Y et al (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure the STARS-BNP Multicenter Study. J Am Coll Cardiol 49:1733–1739

    Article  CAS  PubMed  Google Scholar 

  32. Troughton RW, Frampton CM, Richards AM et al (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130

    Article  CAS  PubMed  Google Scholar 

  33. Hunt SA, Abraham WT, Chin MH et al (2005) ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112(12):154–235

    Article  Google Scholar 

  34. Teles C, Lopes C, Manique A, Moniz D, Sotto-Mayor R, Bugalho de Almeida A (2007) Pulmonary embolism and difficult-to-treat asthma. Rev Port Pneumol 13(6):775–787

    Google Scholar 

  35. Sarazin M, Caumes E, Cohen A, Amarenco P (2004) Multiple microembolic border zone brain infarctions and endomyocardial fibrosis in idiopathic hypereosinophilic syndrome and in Schistosoma mansoni infestation. J Neurol Neurosurg Psychiatry 75(2):305–307

    CAS  PubMed  Google Scholar 

  36. Moore PM, Harley JB, Fauci AS (1985) Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 102(1):109–114

    CAS  PubMed  Google Scholar 

  37. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF (1983) Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 52(205):1–22

    CAS  PubMed  Google Scholar 

  38. Terrier B, Piette AM, Kerob D, Cordoliani F, Tancrède E, Hamidou L, Lebbé C, Blétry O, Kahn JE (2006) Superficial venous thrombophlebitis as the initial manifestation of hypereosinophilic syndrome: study of the first 3 cases. Arch Dermatol 142(12):1606–1610

    Article  PubMed  Google Scholar 

  39. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347(13):969–974

    Article  CAS  PubMed  Google Scholar 

  40. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P (2002) Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 105(5):557–563

    Article  CAS  PubMed  Google Scholar 

  41. Buresly K, Eisenberg MJ, Zhang X, Pilote L (2005) Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165(7):784–789

    Article  CAS  PubMed  Google Scholar 

  42. Turpie AG, Gent M, Laupacis A et al (1993) A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 329(8):524–529

    Article  CAS  PubMed  Google Scholar 

  43. Klion AD, Bochner BS, Gleich GJ et al (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117:1292–1302

    Article  PubMed  Google Scholar 

  44. Metzgeroth G, Walz C, Erben P, Reiter A et al (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 143(5):707–715

    Article  CAS  PubMed  Google Scholar 

  45. Rothenberg ME et al (2008) Treatment of hypereosinophilic syndrome with mepolizumab. N Engl J Med 358:12

    Article  Google Scholar 

  46. Nadarajah S, Krafchik B, Roifman C et al (1997) Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T cell abnormality. Pediatrics 99:630–633

    Article  CAS  PubMed  Google Scholar 

  47. Schneider U, Jenni R, Turina J, Turina M, Hess OM (1998) Long term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart 79:362–367

    CAS  PubMed  Google Scholar 

  48. Metras D, Coulibaly AO, Ouattara K (1985) The surgical treatment of endomyocardial fibrosis: results in 55 patients. Circulation 72:II274–II279

    CAS  PubMed  Google Scholar 

  49. Dubost C, Prigrent C, Gerbaux A, Maurice P, Passeleq J, Rulliere R, Carpentier A, Deloche A (1981) Surgical treatment of constrictive fibrous endocarditis. J Thorac Cardiovasc Surg 82:585–591

    CAS  PubMed  Google Scholar 

  50. Metras D, Coulibaly AO, Ouattara K (1985) The surgical treatment of endomyocardial fibrosis: results in 55 patients. Circulation 72:II274–II279

    CAS  PubMed  Google Scholar 

  51. Moraes C, Buffolo E, Lima R, Victor E, Lira V, Escobar M, Rodrigues J, Saravia L, Andrade J (1983) Surgical treatment of endomyocardial fibrosis. J Thorac Cardiovasc Surg 85:738–745

    CAS  PubMed  Google Scholar 

  52. Joshi R, Abraham S, Kumar AS (2003) New approach for complete endocardiectomy in left ventricular endomyocardial fibrosis. J Thorac Cardiovasc Surg 125(1):40–42

    Article  PubMed  Google Scholar 

  53. Fuzellier JF, Chapoutot L, Torossian PF (2004) Mitral valve repair in idiopathic hypereosinophilic syndrome. J Heart Valve Dis 13(3):529–531

    PubMed  Google Scholar 

  54. Radford DJ, Garlick RB, Pohlner PG (2002) Multiple valvular replacements for hypereosinophilic syndrome. Cardiol Young 12(1):67–70

    Article  PubMed  Google Scholar 

  55. Boustany CW, Murphy GW, Hicks GL (1991) Mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg 51(6):1007–1009

    Article  PubMed  Google Scholar 

  56. Korczyk D, Taylor G, McAlistair H et al (2007) Heart transplantation in a patient with endomyocardial fibrosis due to hypereosinophilic syndrome. Transplantation 83(4):514–516

    Article  PubMed  Google Scholar 

  57. Jeong Yeon Joo (2007) Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics 27:617–637

    Article  PubMed  Google Scholar 

  58. Starr J et al (2000) Myiasis due to hypoderma lineatum infection mimicking the hypereosinophilic syndrome. Mayo Clin Proc 75:755–759

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to acknowledge Princess Ogbogu, M.D., Douglas R. Rosing, M.D., and McDonald K. Horne, III, M.D. Allergy and Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Written informed consent was obtained from the patient for publication of the accompanying images (Figs. 3a, b; 4a, b). A copy of the written consent is available for review by the Editor-in-Chief of this journal. The authors wish also to acknowledge Korczyk D et al. for Fig. 1a, b and Yeon Joo Jeong for Fig. 5a–c.

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Medizinische Klinik I-Kardiologie, University of Rostock, Ernst-Heydemannstr. 6, 18055, Rostock, Germany

    T. Kleinfeldt, C. A. Nienaber, S. Kische, I. Akin, R. G. Turan, T. Körber, H. Schneider & H. Ince

Authors
  1. T. Kleinfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. A. Nienaber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Kische
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Akin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. G. Turan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Körber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Ince
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Kleinfeldt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kleinfeldt, T., Nienaber, C.A., Kische, S. et al. Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol 99, 419–427 (2010). https://doi.org/10.1007/s00392-010-0144-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-010-0144-8

Keywords

Search

Navigation